5National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility testing, Fourteenth Informational Supplement[S]. 2004,M100-S14.
6Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial susceptibility testing; Fifteenth Informational Supplement[S]. 2005, M100-S15.
7Lim WS,Macfarlane JT.Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital:implications for management guidelines[J].Thorax,2001,56 (4):296-301.
8Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for communlty-acquired pneumonia[J]. Am J Med, 2001, 110:451 -457.
9European Respiratory Society. European Study on Community- acquired pneumonia (ESOCAP) Committee. Guidelines for the management of adult community-acquired lower respiratory tract infections[J]. Eur Respir J, 1998, 11:986 -999.
10Niederman MS. Guidelines for the management of community-acquired pneumonia[J]. Med Clin North Am, 2001, 85:1493 -1501.
6123-valent pneumococcal popysaccharide vaccine WHO position paper Weekly Epidemiological Record [ OL]. 2008, 83]373 384 http://www, who. int/wer.
7Training mannual for Enzyme Linked Immunosorbent Assay for the quantitation of Streptococcus pneumoniae serotype specific IgG(Pn PS ELISA). 2011]1-20][OL]]. www. vaccine, uab. edu.
8Hancock DB, Eijgelsheim M, Wilk JB, et al. Meta analyses of ge- nome wide association studies identify multiple lociassociated with pulmonary function[J]. Nat Genet,2010,42(1 ) :45.
9Cill6niz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes[J]. Eur Respir J,2012,40(4) :931-938.
10Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults [J]. Am Fam Physician, 2011,83 (11) : 1299-1306.
